Honeycomb Lung (End-Stage Fibrosis): Treatment and Management Options
Understanding Honeycomb Lung
"Honeycomb lung" describes the CT appearance of end-stage pulmonary fibrosis: clustered cystic airspaces (3–10 mm) with thick walls, resembling a honeycomb. It represents irreversible architectural destruction.
Management Goals
- Slow progression
- Relieve symptoms (dyspnea, cough)
- Improve quality of life
- Prevent/treat complications
Therapeutic Options
| Modality | Details |
|---|---|
| Antifibrotics | Nintedanib, pirfenidone – slow FVC decline in IPF; may be used in other progressive fibrosing ILDs |
| Oxygen therapy | For resting/exertional hypoxemia (SpO₂ <88%); improves survival, exercise capacity, cognition |
| Pulmonary rehabilitation | Exercise training, education, breathing techniques – gold standard for functional improvement |
| Symptom management | Opioids for refractory dyspnea; cough suppressants; treatment of GERD (common comorbidity) |
| Comorbidity control | Treat PH, OSA, CAD, depression/anxiety |
| Lung transplantation | Only curative option; referral early (FVC <50%, DLCO <40%, hypoxemia, rapid decline). Age <70–75, no major comorbidities. |
| Palliative care | Early integration for advance care planning, symptom control, psychosocial support |
Monitoring
- PFTs (FVC, DLCO) every 3–6 months
- 6-minute walk test with oximetry
- HRCT for progression assessment
Multidisciplinary ILD clinic care optimizes outcomes. While honeycomb lung is irreversible, comprehensive management extends meaningful survival.
Asthma - Related Articles
- Singulair (Montelukast): Side Effects, Uses & Information
- Asthma Management: Understanding Interventions & Rehabilitation
- Natural Approaches to Managing Asthma Symptoms
- Natural Asthma Relief: Drug-Free Approaches & Prevention
- Managing Asthma & Cat Allergies: Effective Strategies
- Mouthwash Alcohol and Breathalyzers: False Positive Risk Assessment
- Carpet and Asthma: Understanding the Connection & Solutions